Peter Hecht recruits Bayer/Shire vet Andreas Busch for a top R&D post at his $175M biotech spinout
Image: Peter Hecht. IRONWOOD
Peter Hecht has been a busy man.
In the past two weeks he's unveiled a whopping $175 million raise and spun out a fully formed biotech out of Ironwood — Cyclerion Therapeutics — securing a public listing for a company with 140 staffers and a pipeline of drugs presenting 4 catalysts over the course of this year. And now he's built out his top executive team after wooing Bayer/Shire vet Andreas Busch to take the job of chief innovation officer.
Busch will be working alongside CSO Mark Currie.
Basic subscription required
Unlock this story instantly and join 53,100+ biopharma pros reading Endpoints daily — and it's free.